Poseida Therapeutics(PSTX) - 2023 Q2 - Earnings Call Presentation

Financial Investment and Strategic Rights - Astellas is investing $50 million in Poseida, comprising $25 million to acquire approximately 8.8% of Poseida's common stock and an additional $25 million for certain strategic rights[6] - The funds from the Astellas investment will support the development of Poseida's cell therapy programs and for general corporate purposes[27] - Astellas receives a right of exclusive negotiation and first refusal to license P-MUC1C-ALLO1, along with a Board observer seat for 18 months, while Poseida retains ownership and control of P-MUC1C-ALLO1[66] Allogeneic CAR-T Therapy Pipeline - Poseida is focused on developing off-the-shelf cell therapies for both solid and liquid tumors[29] - Poseida's allogeneic CAR-T pipeline includes P-MUC1C-ALLO1 for solid tumors, P-PSMA-ALLO1 for prostate and salivary gland cancers, and P-BCMA-ALLO1 for multiple myeloma, with P-BCMACD19-ALLO1 and P-CD19CD20-ALLO1 also in development for multiple myeloma and B-cell malignancies respectively[75,88] - P-CD19CD20-ALLO1, a dual CAR-T program, received FDA IND clearance in June 2023 and demonstrates high T stem cell memory (TSCM) and strong in vivo cytotoxicity against xenograft models of CLL and lymphoma[100] Gene Therapy Programs - Poseida is focused on liver-directed gene therapy for rare diseases, with an initial focus on this area[49] - The company's gene therapy pipeline includes P-OTC-101 for Ornithine Transcarbamylase Deficiency (OTCD), P-FVIII-101 for Hemophilia A, and P-PAH-101 for Phenylketonuria (PKU)[58,59,60] - In preclinical studies, piggyBac+AAV enabled permanent and stable DNA integration and long-term expression in gene therapy applications[110]